WVP
AKBA icon

Worth Venture Partners’s Akebia Therapeutics AKBA Stock Holding History

Worth Venture Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-63,500
Closed -$46K – 149
2022
Q1 		$46K Buy
+63,500
New +$136K 0.02% 129

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Worth Venture Partners's AKBA Position: Q2 2022 in Review

Worth Venture Partners sold out of Akebia Therapeutics (AKBA) in Q2 2022, closing a stake of 63,500 shares — an estimated $46K sold.

Worth Venture Partners first reported a position in AKBA in Q1 2022 and held it in 1 quarter. The position peaked at $46K in Q1 2022. 96 funds tracked by Wall St. Rank hold AKBA as of Q2 2022.

  • Worth Venture Partners reported no remaining Akebia Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Worth Venture Partners sold 63,500 Akebia Therapeutics shares in Q2 2022, an estimated $46K.
  • Worth Venture Partners first reported a position in Akebia Therapeutics in Q1 2022 and held it in 1 quarter.
  • Worth Venture Partners's Akebia Therapeutics position peaked at $46K in Q1 2022.
  • 96 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2022.

Based on Worth Venture Partners's 13F filing for Q2 2022, filed 15 Aug 2022.